The article discusses the potential of artificial intelligence (AI) to accelerate the discovery of new cancer treatments. It highlights the work of researchers at the Institute of Cancer Research (ICR) in London, who are using AI to analyze vast amounts of data on cancer biology and identify promising new drug targets. The key points are: 1) AI can rapidly sift through massive datasets, identifying patterns and connections that humans might miss. 2) Researchers at ICR have developed an AI system called REVOLVER that can analyze data on gene activity, protein structures, and drug-target interactions to pinpoint potential new cancer drug targets. 3) REVOLVER has already identified several promising targets for cancers like acute myeloid leukemia. 4) AI could significantly speed up the drug discovery process, which currently takes over a decade and costs billions. 5) However, AI is a tool to assist human researchers, not replace them. Experts caution that AI systems can be biased and may miss important factors that humans would recognize.